News Related to Alphamab Oncology

Related coverage linked through entity extraction aliases.

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN003 for HER2-Positive CRC

Feb 15, 2026

Alphamab Oncology dosed the first patient in its Phase III trial of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, for HER2-positive advanced colorectal cancer on February 14, 2026.

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN003 for Colorectal Cancer

Feb 14, 2026

Alphamab Oncology has dosed the first patient in a Phase III study of JSKN003, a biparatopic HER2-targeting ADC, for HER2-positive advanced colorectal cancer. The drug demonstrated a 68.8% response rate in earlier trials.